StopRA: National Network to Prospectively Study Individuals At-Risk for Rheumatoid Arthritis

Primary Objective

The goal of this study is to create a national network to study individuals at-risk for developing Rheumatoid Arthritis. This will be done through two objectives Objective #1) Establish the infrastructure to identify and follow antibodies to citrullinated protein antigens (ACPA) positive individuals who have been identified through routine care at rheumatology clinical practices or previously established research studies across the USA. This will provide data to inform objective #2 (see below) as well as serve as infrastructure that can be used in the future to recruit and enroll subjects for prevention and/or early treatment trials in RA. Objective #2) Develop robust predictive models for the 'real world' development of RA using clinical, environmental and biomarker (autoantibody and genetic) factors.

Is This Study For You?

Let's Get Started!

Description

This study is designed to help us learn more about the development of rheumatoid arthritis (RA). This study is going to be a national study following people who have an abnormal blood test that is related to rheumatoid arthritis (RA). This test is called ‘anti-CCP’ and can be a marker for developing RA in the future. By studying people who have this abnormal CCP test, we hope that we will be able to develop better models for understanding the ‘real world’ development of RA. We plan to do this using clinical information, environmental information and results from blood tests done in this study to learn more about how RA develops, and ultimately how to prevent RA. Individuals can join the study from a variety of different paths, including identified through routine care at rheumatology clinical practices, previously established research studies across the USA, or can been tested through step 1 of this study where we test your CCP level.

Details
Age
Adult
Eligibility
Anyone who is CCP+ without a diagnosis of RA, or taking medicines that treat RA or other autoimmune diseasesInclusion criteria • ACPA positive by any clinically-used ACPA test. These can include anti-cyclic citrullinated peptide (anti-CCP)-2, anti-CCP3 and anti-CCP3.1. • Absence of historical or current clinically-apparent inflammatory arthritis that would, in the opinion of their rheumatology clinician, warrant current disease-modifying therapy, and absence of prior use of disease-modifying therapy. • Ability to complete on-line assessments including self-reported disease measures and undergo locally-performed blood draws and buccal swab collection at home. • The participant's rheumatologist is willing to participate in the study and provide clinical assessments to the study (this is a conditional criteria as participants can participate if their rheumatologist is unable to participate). • Age >=18 years old at the time of study enrollment. There will be no upper age limit.
Locations

Barbara Davis Center

Principal Investigator
Photograph of Kevin Deane

Kevin Deane

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers